PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+CD57+PD-1-MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL